The outbreak of novel coronavirus 2019-nCoV ("Coronavirus") is an extraordinary challenge for many transactions involving Chinese companies. In this section, we analyse its impact on certain key aspects of mergers and...more
2/18/2020
/ Best Practices ,
China ,
Coronavirus/COVID-19 ,
Corporate Sales Transactions ,
Covered Transactions ,
Financial Markets ,
Force Majeure Clause ,
Infectious Diseases ,
Investment ,
Investor Protection ,
Investors ,
Joint Venture ,
Market Conditions ,
Material Adverse Effects ,
Public Health ,
Risk Management ,
Share Purchase Agreements